EMA CHMP gives positive opinion on isatuximab combination for newly diagnosed myeloma patientsAccess, Myeloma, News20 November 2024
MPE comments on the Implementing Regulation on joint scientific consultations on medicinal products for human use at Union levelAccess, News29 October 2024
During European Myeloma Day, MPE highlights the importance of improving access to clinical trialsAccess, MPE, Myeloma27 September 2024
EMA recommends a new indication for daratumumab in adult patients with newly diagnosed myeloma who are eligible for autologous stem cell transplantAccess, Myeloma26 September 2024
A second bispecific antibody is approved as a fourth-line treatment for myeloma in England and WalesAccess, Myeloma, News17 July 2024
The National Institute for Health and Care Excellence (NICE) approves the use of elranatamab as a fourth-line treatment for myeloma in England and WalesAccess, Myeloma9 July 2024
MPE comments on the second implementing act of the EU health technology assessment (HTA) regulation (EU HTAR)Access, MPE26 June 2024
European Commission approves CAR T-cell therapy ciltacabtagene autoleucel in earlier lines of therapy for relapsed and refractory myelomaAccess, CAR-T, Myeloma23 April 2024
MPE launches the Myeloma and AL Amyloidosis European Clinical Trial NavigatorAccess, AL amyloidosis, MPE, Myeloma23 April 2024
Q&A: US Food and Drug Administration (FDA) approves MRD as a basis for accelerated approval in myelomaAccess, MPE, Myeloma18 April 2024
